Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.

Original reporting
Published Aug 13, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover? — source image
Decision brief

The 30-second read

$PBHNeutralMed
01

Why it matters

The key trading debate is whether acquisition-driven revenue growth and integration completion can offset near-term margin pressure and higher interest/amortization from new debt, especially with Clear Eyes supply volatility expected into the second quarter.

02

Market read

Guidance was raised for FY27 sales and adjusted EPS, but the article highlights near-term supply-driven volatility and financing costs that can drive earnings estimate revisions.

03

What to watch

Transportation cost and product mix drove gross margin down 120 bps; if those persist, acquisition-driven revenue growth may not translate into EPS upside as assumed.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session positioning following the Aug 6 earnings call recap and FY27 guidance update

Background

Prestige Consumer Healthcare is integrating two recently closed acquisitions (Breathe Right and LaCorium Health) while managing a legacy Clear Eyes manufacturing constraint.

Company-level read

Ticker impact

$PBHNeutralMedium confidence
Context

Prestige says it closed Breathe Right (June 12) and LaCorium Health (July 1), raising FY27 sales and adjusted EPS guidance while Clear Eyes faces a supply bottleneck.

Expected impact

Choppy trading likely around leverage/interest-cost concerns versus confidence in integration and second-half stabilization.

Evidence & confidence

The article provides concrete deal timing, guidance ranges, and quantified debt/interest/amortization impacts, but it is still an editorial framing rather than a fresh filing or print.

Market effects

Signals continued consolidation in consumer healthcare and that integration execution plus manufacturing throughput are key swing factors for margins.

Limited direct regional read-through; mentions international organic decline tied to distributor timing rather than demand collapse.

Deal adds brands sold in 20+ countries, but the article’s actionable focus is company-specific guidance and leverage.

Counterpoint

The guidance lift may be more debt-financed than organic, and Clear Eyes bottleneck could persist longer than management’s back-half stabilization timeline.

Key entities

  • Prestige Consumer Healthcare

    NYSE-listed consumer healthcare company anchoring its portfolio with Dramamine and Compound W, and integrating Breathe Right and LaCorium Health.

  • Breathe Right

    Brand acquired June 12, expected to add about $200 million in annual revenue and launching new Sport strip variants.

  • LaCorium Health

    Dermal therapy brand acquired July 1, adding about $40 million in annualized revenue and expanding eczema and cold sore exposure.

  • Clear Eyes

    Legacy eye care brand facing a manufacturing bottleneck at the Pillar5 facility, driving near-term sales volatility.

Related articles

$PBHMed

Prestige Consumer Healthcare Q2 Earnings Call Highlights

Prestige Consumer Healthcare (PBH) lowered its full-year Clear Eyes sales forecast to under $20M, citing production issues. Q3 revenue is expected at $328M with EPS of $1.05. Recent acquisitions Breathe Right and LaCorium contributed $71M in H1 revenue. The company plans to prioritize debt reduction, with net debt at $2.1B. E-commerce sales growth continues at a mid-teens rate.

$PBHMed

Prestige Consumer Healthcare Inc (PBH) (Q2 2027) Earnings Call Highlights: Revenue Surges

Prestige Consumer Healthcare (PBH) reported Q2 2027 revenue growth of 23%, with EBITDA margin at 34%. The company prioritized debt reduction, leaving $90M in share repurchase authorization. Organic brands performed well, with GI brands benefiting from GLP-1 marketing. Women's Health saw slight quarterly growth but year-to-date decline. Acquisitions Breathe Right and Liquorium showed strong early results.

$PBHMedAI 8/10

Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript

Prestige Healthcare (PBH) reported Q2 2027 earnings, with revenue up 23% to $336.3M, driven by acquisitions and organic growth. Adjusted EPS rose 6% to $1.13. The company integrated Breathe Right and LaCorium, expecting long-term growth. eCommerce sales grew mid-teens, with investments in digital media and content.